PepTalk 2017
PepTalk 2017
Archived Content

Recombinant Protein Therapeutics

Day 1 | Day 2 | Download Brochure


7:30 am Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee


Engineering to Fight Disease

8:15  Chairperson's Remarks

Stefan Schmidt, Ph.D., M.B.A., CEO/CSO, XL-Biologics GmbH

8:20  Antagonistic VEGF Variants Engineered to Simultaneously Bind to and Inhibit VEGFR2 and AlphaV Beta3 Integrin

Jennifer CochranJennifer Cochran, Ph.D., Assistant Professor, Bioengineering, Stanford University - Speaker Biography

We used an antagonistic VEGF ligand as a molecular scaffold to engineer dual-specific proteins that simultaneously bound to VEGFR2 and alphav beta3 integrin with antibody-like affinities. These dual-specific proteins more potently inhibited angiogenic processes in vitro and in vivo compared to mono-specific targeting agents. Instead of relying on antibody associating domains or physical linkage, this work highlights an approach to creating dual-specific proteins where additional functionality is introduced into a protein ligand to complement its existing properties.

8:50 Next Generation Immuno-Therapy of Cancer: Development of a Disialoganglioside Specific Immuno-Cytokine

Manfred SchusterManfred Schuster, Ph.D., COO, APEIRON Biologics AG - Speaker Biography

This talk will give insight into the development history of the immuno-cytokine hu14.18-IL2, a fusion protein consisting of the humanized 14.18 anti-disialoganglioside monoclonal antibody genetically linked to human recombinant interleukin-2. GD2 disialoganglioside is highly expressed on neuroblastoma tumor cells. Despite multimodal intensive therapy, less than half of the patients with high-risk disease are cured and therefore new and innovative approaches are needed. This immuno-cytokine has shown first hints of efficacy and an acceptable tolerability profile in a pediatric Phase I study.

9:20 Site-Specific Crosslinking of Proteins Using Swift Linkage Multivalent Technology

Allen KrantzAllen Krantz, Ph.D., President & CEO, Advanced Proteome Therapeutics, Inc. - Speaker Biography

Advanced Proteome Therapeutics has developed Swift Linkage Multivalent Technology (SLMT) to rapidly link proteins, peptides and organic chemical pharmacophores to protein sites, site specifically. Using SLMT protein dimers can be prepared within 24 hours site-specifically, biologically active, and in good yield. Examples will be discussed that illustrate the mechanistic principles underlying the technology and specific examples that complement rival recombinant methods.

Macromolecule Delivery into Mammalian Cells Using Supercharged Proteins, Poster A304

James Cronican, Chemical Biology, Harvard University 

10:05 Networking Coffee Break in the Exhibit Hall with Poster Viewing


Targeting Protein/Protein Interactions

10:45 Targeting Protein/Protein Interactions with Engineered Cyclotides

Julio CamareroJulio Camarero, Ph.D., Associate Professor, Pharmacology and Pharmaceutical Sciences, University of Southern California, Los Angeles - Speaker Biography

Cyclotides have several characteristics that make them ideal drug development tools. First, they are remarkably stable due to the cystine knot. Second, they are small, making them readily accessible to chemical synthesis. Third, they can be encoded within standard cloning vectors, and expressed in bacteria or animal cells, and are amenable to substantial sequence variation. We will be presenting our ongoing effort for the selection of novel cycotide sequences able to target protein/protein interactions involved in the p53 pathway.

11:15 Protein-Fragment Complementation and Semi-Rational Design: Engineering Specific Antagonists of Protein-Protein Interactions

Jody MasonJody M. Mason, Ph.D., Senior Lecturer, Biochemistry, University of Essex

We are designing and generating a range of peptide antagonists capable of inhibiting protein-protein interactions with high affinity and specificity. We extensively use protein-fragment complementation for antagonist selection. The efficacy of derived and designed sequences that confer specificity are then tested in vivo and in vitro. These techniques are also being applied to a range of therapeutically relevant systems including the transcriptional regulator AP-1, as well as β-amyloid and α-synuclein proteins, the primary factors implicated in the pathogenesis of Alzheimer's and Parkinson's diseases.

11:45 Trivalent Atrimers Therapeutics: A New Grasp on Receptors for Potent Protein Therapeutics

Anke Kretz RommelAnke Kretz-Rommel, Ph.D., Vice President, Research & Development, Anaphore, Inc. - Speaker Biography

Atrimer Therapeutics are tetranectin-based proteins programmable in their three binding domains to specifically block or activate disease relevant proteins. The trivalent nature and overall structure of Atrimer proteins allows for high avidity interaction with their target, and its footprint is uniquely suited to mimic trimeric ligands in their ability to activate trimeric receptors, or to cross-link mono- or dimeric receptors. Atrimer therapeutics also show great potential to deliver drug conjugates through internalizing receptors. We will present the latest data on a number of receptor targeting Atrimer proteins with great therapeutic potential.

12:15 pm Engineering CHO Cell Line For Enhanced Production of MAbs and Fc:Fusion Proteins 
Pierre-Alain Girod, Ph.D., Chief Scientific Officer, Selexis
The Chinese hamster ovary (CHO) cell line is the predominant host for the production of therapeutic proteins. However, the CHO cell remains poorly efficient in the production at high level of certain classes of proteins such as fusion proteins. We have identified components of the secretion network able to enhance the yield of recombinant proteins. Co-expression of secretion components improved cell lines expression at protein concentrations greater than 1 gr/L in a fed-batch process. We have thus developed new designer cell lines metabolically engineered to overcome the specific expression bottlenecks associated with difficult-to-express proteins.

12:45 Luncheon Presentations (Sponsorship Opportunity Available) or Lunch on Your Own

2:00 BuzZ Session A

2:45 Networking Refreshment Break in Exhibit Hall with Poster Awards

3:30 BuzZ Session B

4:15 End of Conference; 4:15 Registration for Short Courses

4:30 – 7:30 Concurrent Dinner Short Courses (SC5-SC9)*

*Separate Registration Required.

Day 1 | Day 2 | Download Brochure

Links to Companion Meetings

Pipeline 3

Antibodies for the 21st Century

Bispecific Antibody Therapeutics